Results From a Phase I/II Trial of Cusatuzumab Combined With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

This two-part, open-label, multicenter, Phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients received a single dose of cusatuzumab at one of four dose levels 14 days before starting combination therapy.